Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma.

Biochemical pharmacology - 1 Aug 2011

Fedorenko Inna V, Paraiso Kim H T, Smalley Keiran S M

Abstract excerpt

The discovery of activating BRAF V600E mutations in 50% of all cutaneous melanomas has revolutionized the understanding of melanoma biology and provided new strategies for the therapeutic management of this deadly disease. Highly potent small molecule inhibitors of BRAF are now showing great promise as a novel therapeutic strategy for melanomas harboring activating BRAF V600E mutations and are associated with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cancer Mechanisms and Therapy
Share to BRAF gene

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Gene Expression Regulation, Neoplastic

Share to Melanoma

Share to Melanoma and MAPK Pathways

Share to Mutation

Share to Proto-Oncogene Proteins B-raf

Source

Open in PubMed Open full text

Identifiers

PMID: 21635872
DOI: 10.1016/j.bcp.2011.05.015
PMCID: PMC4001781

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma.PMID 21635872Read ↗

Emerging insights into resistance to BRAF inhibitors in melanoma.Semantic proximity Read ↗

Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies.Semantic proximity Read ↗

BRAF Inhibitor Resistance in Melanoma: Mechanisms and Alternative Therapeutic Strategies.Semantic proximity Read ↗

A Review of the Molecular Pathways Involved in Resistance to BRAF Inhibitors in Patients with Advanced-Stage Melanoma.Semantic proximity Read ↗

Targeted therapy in BRAF‑mutant melanoma: Advances and challenges (Review).Semantic proximity Read ↗

Targeting BRAF in melanoma: biological and clinical challenges.Semantic proximity Read ↗

Detecting mechanisms of acquired BRAF inhibitor resistance in melanoma.Semantic proximity Read ↗

BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and ResistanceSemantic proximity Read ↗

BRAF in melanoma: current strategies and future directions.Semantic proximity Read ↗

Emerging BRAF inhibitors for melanoma.Semantic proximity Read ↗

BRAF Inhibitors and MelanomaSemantic proximity Read ↗

Clinical Implications of Acquired BRAF Inhibitors Resistance in Melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.